<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">antibiotics-247</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Эффективность Ингавирина® in vitro в отношении возбудителя аденовирусной инфекции</article-title><trans-title-group xml:lang="en"><trans-title>In vitro Ingavirin® Efficacy Against Adenoviral Infection Pathogen</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Логинова</surname><given-names>С. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Loginova</surname><given-names>S. YA.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борисевич</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Borisevich</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimov</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бондарев</surname><given-names>В. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Bondarev</surname><given-names>V. P.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Небольсин</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Nebolsin</surname><given-names>V. E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Филиал федерального государственного учреждения «48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации» — «Вирусологический центр», Сергиев Посад</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Branch of Central Research Institute No. 48, Ministry of Defense of the Russian Federation, Virological Centre, Sergiev Posad</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Открытое акционерное общество «Валента Фармацевтика», Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Valenta Farmacevtica, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>05</month><year>2020</year></pub-date><volume>54</volume><issue>7-8</issue><fpage>16</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; ООО «Издательство ОКИ», 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">ООО «Издательство ОКИ»</copyright-holder><copyright-holder xml:lang="en">ООО «Издательство ОКИ»</copyright-holder><license xlink:href="https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/247">https://www.antibiotics-chemotherapy.ru/jour/article/view/247</self-uri><abstract><p>Экспериментальное изучение противовирусной эффективности Ингавирина® свидетельствует, что в концентрациях 200 и 100 мкг/мл препарат полностью защищает клетки от цитопатического действия вируса при внесении его до заражения культуры клеток HeLa. При 10-кратном снижении инфицирующей дозы вируса до 0,001 ЦПД50/клетку подавление цитопатического эффекта вируса Ингавирином® составило 100% во всех изученных концентрациях (в том числе и низких) как при внесении препарата до, так и после инфицирования. Ингавирин® эффективно подавляет репродукцию аденовируса 5 типа в культуре клеток HeLa.</p></abstract><trans-abstract xml:lang="en"><p>The experimental investigation of the Ingavirin® antiviral effect showed that in concentrations of 200 and 100 mcg/ml it totally protected the cells from the cytopathic action of the virus, when added before the inoculation of the HeLa cell culture. After a tenfold decrease of the infective dose (up to 0.001 CPD50/cell), the inhibition of the virus cytopathic effect by Ingavirin® amounted to 100% in all the tested concentrations (including the low ones) added either before or after the culture contamination. Ingavirin® was efficient in inhibition of the adenovirus type 5 reproduction in the HeLa cell culture.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Ингавирин®</kwd><kwd>аденовирус</kwd><kwd>культура клеток</kwd><kwd>противовирусная эффективность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Ingavirin®</kwd><kwd>adenovirus</kwd><kwd>cell culture</kwd><kwd>antiviral effect</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Virus taxonomy: The classification and nomenclature of viruses. The seventh report of the International Committee on Taxonomy of Viruses. Eds. by M. H. V. Regenmortel, C. M. Fauquet, D. H. L. Bishop et al. Acad. Press., San Diego, 2000.</mixed-citation><mixed-citation xml:lang="en">Virus taxonomy: The classification and nomenclature of viruses. The seventh report of the International Committee on Taxonomy of Viruses. Eds. by M. H. V. Regenmortel, C. M. Fauquet, D. H. L. Bishop et al. Acad. Press., San Diego, 2000.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Колобухина Л. В., Львов Д. К. Вирусные инфекции дыхательных путей / Медицинская вирусология. Под ред. академика РАМН Д. К. Львова. М.: 2008; 408—411.</mixed-citation><mixed-citation xml:lang="en">Колобухина Л. В., Львов Д. К. Вирусные инфекции дыхательных путей / Медицинская вирусология. Под ред. академика РАМН Д. К. Львова. М.: 2008; 408—411.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">De Oliveira C. B., Stevenson D., La Bree et al. Evolution of cidofirm (HPMPC, GS-504) against adenovirus type 5 infection in a New Zealand rabbit ocular model. Antiviral Res 1996; 31: 165—172.</mixed-citation><mixed-citation xml:lang="en">De Oliveira C. B., Stevenson D., La Bree et al. Evolution of cidofirm (HPMPC, GS-504) against adenovirus type 5 infection in a New Zealand rabbit ocular model. Antiviral Res 1996; 31: 165—172.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Duggan J. M., Farrehi J., Duderstadt S. et al. Treatment with ganciclovir of adenovirus pneumonia in cardiac transplant patient. Am J Med 1997; 103: 5: 439—440.</mixed-citation><mixed-citation xml:lang="en">Duggan J. M., Farrehi J., Duderstadt S. et al. Treatment with ganciclovir of adenovirus pneumonia in cardiac transplant patient. Am J Med 1997; 103: 5: 439—440.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Галабов А. С., Галегов Г. А. Методические аспекты химиотерапии вирусных инфекций. Acta virol 1978; 22: 4: 343—351.</mixed-citation><mixed-citation xml:lang="en">Галабов А. С., Галегов Г. А. Методические аспекты химиотерапии вирусных инфекций. Acta virol 1978; 22: 4: 343—351.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Чижов Н. П. Методические вопросы научной разработки противовирусных препаратов. Минск, 1977: 36—41.</mixed-citation><mixed-citation xml:lang="en">Чижов Н. П. Методические вопросы научной разработки противовирусных препаратов. Минск, 1977: 36—41.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
